The University of Southampton
University of Southampton Institutional Repository

Galantamine: a randomised, double-blind, dose-finding trial in patients with Alzheimer's disease

Record type: Article

Objectives: to investigate whether Galantamine significantly improves the core symptoms of Alzheimer's disease (AD).
Background: galantamine is a reversible, competitive, selective inhibitor of acetylcholinesterase (AChE) that also allosterically modulates nicotinic acetylcholine receptors. This dual mechanism of action provided the rationale for a phase II trial of galantamine in AD.
Method: a multicentre, randomized, parallel, double-blind, placebo-controlled trial was carried out to evaluate the efficacy and tolerability of galantamine 18, 24 and 36 mg/day administered for 3 months in 285 patients with mild-to-moderate probable AD. The primary outcome measure was the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog); secondary outcome measures were the Clinical Global Impression of Change (CGIC) and the Progressive Deterioration Scale (PDS).
Results: patients treated with galantamine 24 mg/day had a significantly better outcome than placebo on ADAS-cog; the treatment difference was 3 points on the intention-to-treat (ITT) analysis ( p = 0.01) and 4.2 points on per protocol analysis ( p = 0.001). Per protocol analysis showed that galantamine had a significantly better outcome than placebo on PDS ( 24-mg/day dose, p < 0.05) and CGIC (36-mg/day dose, p < 0.05). Galantamine was well tolerated at the lower doses of 18 and 24 mg/day where it produced mild, transient effects typical of cholinomimetic agents.
Conclusion: this study shows that, relative to placebo, galantamine significantly improves the core symptoms of Alzheimer's disease.

Full text not available from this repository.

Citation

Wilkinson, D. and Murray, J. (2001) Galantamine: a randomised, double-blind, dose-finding trial in patients with Alzheimer's disease International Journal of Geriatric Psychiatry, 16, (9), pp. 852-857. (doi:10.1002/gps.409).

More information

Published date: 2001
Keywords: galantamine, dementia, Alzheimer's disease, acetylcholinesterase inhibitor

Identifiers

Local EPrints ID: 27742
URI: http://eprints.soton.ac.uk/id/eprint/27742
PURE UUID: f64c9d05-c892-4145-9dd3-ffd1df5cb8c7

Catalogue record

Date deposited: 27 Apr 2006
Last modified: 17 Jul 2017 16:03

Export record

Altmetrics

Contributors

Author: D. Wilkinson
Author: J. Murray

University divisions


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×